Blog

VANCOUVER, British Columbia, March 28, 2024 (GLOBE NEWSWIRE) — Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada licensed psychedelics pharmaceutical manufacturer, specializing in controlled substances such as natural psilocybin and MDMA, proudly announces its role as a Presenting Sponsor at the highly anticipated 4th Annual Psychedelic Therapeutics and Drug Development Conference. The event is scheduled to take place in Boston, Massachusetts on May 23-24, 2024. The 4th Annual Psychedelic Therapeutics and Drug Development Conference convenes renowned researchers and esteemed leaders from academia, industry, non-profit organizations, and government sectors to explore the challenges and opportunities inherent…

VANCOUVER, BC, March 28, 2024 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) (“Filament” or the “Company”), a clinical‐stage natural psychedelic drug development company, today announced the appointment of Michael Messinger, CPA, to its Board of Directors (the “Board“). Mr. Messinger will also serve as the Chair of the Company’s Audit Committee. “I am pleased to welcome Mr. Messinger to our Board of Directors,” said Filament Chief Executive Officer, Benjamin Lightburn. “We welcome his many decades of experience in both finance and biotechnology, and look forward to leveraging his expertise as we work to advance Filament’s drug development platform.” Mr. Messinger has…

Horizons: Perspectives on Psychedelics stands as a beacon for those intrigued by the enigmatic world of psychedelic research and culture. As Horizons approaches its 16th year, this seminal event promises to unfold over three enlightening days, from May 9-11, 2024, at the prestigious New York Academy of Medicine. This year’s gathering is not just an event but a journey into the heart of psychedelic discovery, bridging the gaps between science, medicine, policy, culture, and spirituality. Table of Contents Introduction to Horizons: Perspectives on Psychedelics 2024 In the bustling heart of New York City, a unique convergence of minds is set…

atai Life Sciences, trading under NASDAQ:ATAI and ETR:9VC, recently announced the encouraging findings from a study conducted by its investee, Beckley Psytech, on a pioneering DMT formulation, BPL-003, for individuals struggling with treatment-resistant depression. During this open-label Phase 2a investigation, a select group of patients received a single dose of BPL-003. This novel, synthetic formulation of 5-MeO-DMT, known as mebufotenin, presented in the form of a benzoate salt, was administered intranasally alongside psychological support. Remarkably, 55% of participants exhibited a rapid antidepressant response merely a day following the treatment. The study focused on 12 individuals diagnosed with moderate-to-severe depression that…

OXFORD, United Kingdom–(BUSINESS WIRE)– Beckley Psytech Ltd, the private, clinical-stage biopharmaceutical company dedicated to improving the lives of people living with neuropsychiatric disorders by developing effective and rapid-acting psychedelic medicines, today announced positive initial findings from its Phase IIa clinical study (NCT05660642) of BPL-003 for Treatment Resistant Depression (TRD). BPL-003 is Beckley Psytech’s novel, synthetic, patent-protected benzoate salt formulation of 5-MeO-DMT (Mebufotenin) and is administered intranasally. Initial results show that a single 10mg dose of BPL-003 was well-tolerated with a short treatment duration and rapid, durable efficacy in patients with TRD. The open-label Phase IIa study investigated the safety, efficacy…